Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

iShares 3 7 Year Treasury Bond ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

iShares 3 7 Year Treasury Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.47, while Vertex Pharmaceuticals Incorporated trades at $526.56 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

IEIVRTX
Sector
Fixed IncomeHealth
52-Week High
$120.72$529.65
52-Week Low
$116.16$376.62
Market Cap
$134.25B
Enterprise Value
$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 3 7 Year Treasury Bond ETF

IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% on the day, amid a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a steady dividend payout schedule, with recent distributions around $0.37 per share. Market sentiment is influenced by rising Treasury yields and inflation concerns, as highlighted in recent financial news.

The outlook for IEI is cautious due to potential Federal Reserve rate hikes and inflation pressures, which could pressure bond prices. Opportunities lie in its government backing and lower volatility, but risks include interest rate sensitivity and macroeconomic shifts affecting yield curves.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.

The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.

Returns comparison

Trailing returns across standard periods

About iShares 3 7 Year Treasury Bond ETF

IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.

Read more on IEI

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX